An interventional study of Alcovit® (Zeolite Clinoptilolite) and Placebo in Alcohol Drinking, Blood Alcohol Content and Hangover, sponsored by Galzu Institute of Research, Teaching, Science and Applied Technology. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Galzu Institute of Research, Teaching, Science and Applied Technology · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if Alcovit® (zeolite clinoptilolite) works to reduce blood alcohol concentration in healthy adults aged 18-70 years who are occasional or moderate alcohol consumers. It will also learn about the safety and tolerability of Alcovit®. The main questions it aims to answer are:
Researchers will compare Alcovit® administered before alcohol consumption, Alcovit® administered after alcohol consumption, placebo administered before alcohol consumption, and placebo administered after alcohol consumption to see if Alcovit® effectively reduces blood alcohol levels.
Participants will:
The product has extensive international experience, having been marketed in several countries (Germany, Poland, Romania, Russia, Australia, Mexico, Colombia, Croatia, United States, Ukraine and Sweden) over the past 15 years, totaling 1,387,500 sachets sold without reports of toxicity.
The safety of clinoptilolite zeolite has been extensively evaluated by the European Food Safety Authority (EFSA) and by clinical trials, which confirmed its safety at typical food exposure levels, with no toxic side effects observed in humans or animals, even with prolonged use.
Alcovit® is formulated as an effervescent powder for suspension presented in 15g sachets and intended for healthy adults who are occasional or moderate consumers of alcoholic beverages.
The mechanism of action of Alcovit® is based on the ability of clinoptilolite zeolite to adsorb alcohol molecules in the stomach and small intestine, preventing their systemic absorption and promoting their natural elimination through the gastrointestinal tract.
703 studies on the registry are indexed under Alcohol Drinking; 132 are open to participants now.
This study's planned enrollment of 228 is above the median of 125 across 609 interventional studies indexed under Alcohol Drinking.
Browse Alcohol Drinking studies →Galzu Institute of Research, Teaching, Science and Applied Technology is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the investigational device immediately before (2-3 minutes) consuming the standardized alcohol dose.
Device: Alcovit® (Zeolite Clinoptilolite)
Participants receive the investigational device immediately after (maximum 5 minutes) consuming the standardized alcohol dose.
Device: Alcovit® (Zeolite Clinoptilolite)
Participants receive the placebo immediately before consuming the standardized alcohol dose.
Device: Placebo
Participants receive the placebo immediately after consuming the standardized alcohol dose.
Device: Placebo
Effervescent powder for oral suspension presented in 15g sachets, containing zeolite clinoptilolite (approximately 96% of the formulation) associated with B-complex vitamins (B1, B6, B12), vitamin C, and cupric chlorophyllin as natural colorant. The device is administered either immediately before alcohol consumption (2-3 minutes prior) or immediately after alcohol consumption (maximum 5 minutes after) depending on the assigned study arm.
Also known as: Alcovit (Pre-consumption), Alcovit (Post-consumption)
Effervescent powder for oral suspension presented in 15g sachets. Inert substance with identical appearance, taste, and texture to Alcovit®, but without the active ingredient (zeolite clinoptilolite). The placebo is administered either immediately before alcohol consumption (2-3 minutes prior) or immediately after alcohol consumption (maximum 5 minutes after) depending on the assigned study arm.
Also known as: Placebo (Pre-consumption), Placebo (Post-consumption)
Reduction in Blood Alcohol Levels and Breathalyzer Readings - Pre-consumption Administration
Analysis of the reduction in blood alcohol levels and breathalyzer (ethylometer) readings in the Alcovit® group compared to the placebo group before alcohol consumption.
Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)
Reduction in Blood Alcohol Levels and Breathalyzer Readings - Post-consumption Administration
Analysis of the reduction in blood alcohol levels and breathalyzer (ethylometer) readings in the Alcovit® group compared to the placebo group after alcohol consumption.
Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1).
Correlation Between Blood Alcohol Reduction and Breathalyzer Readings
Correlation between the reduction in blood alcohol levels and breathalyzer (ethylometer) readings.
Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)
Correlation Between Elimination Rate in Blood and Breathalyzer
Correlation between the elimination rate of alcohol in blood and breathalyzer (ethylometer) readings.
Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1).
Hangover Symptom Severity Using AHSS
Evaluation of Alcovit® efficacy in mitigating hangover symptoms using the total score and subdomains of the Alcohol Hangover Severity Scale (AHSS).
Time frame: 24 hours after alcohol consumption (Day 1)
Participant Experience with Alcovit® (Patient-Reported Outcomes)
Participant experience with Alcovit® assessed by participant questionnaire.
Time frame: Day 1 to Day 2
Adverse Events Reported by Participants (Clinician-Reported Outcomes)
Analysis of adverse events reported by participants.
Time frame: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)
Number and Type of Adverse Events (Clinician-Reported Outcomes)
Number and type of adverse events, unexpected adverse events, and serious adverse events.
Time frame: Day 1 to Day 44 (6 weeks)
Changes in Hepatic Function Markers (Clinician-Reported Outcomes)
Changes in hepatic function between Alcovit® administration groups before and after alcohol ingestion (distilled and fermented beverages) compared to control for AST, ALT, GGT, alkaline phosphatase (ALP), total bilirubin and fractions.
Time frame: Day 1 to Day 44 (6 weeks)
Changes in Renal Function Markers (Clinician-Reported Outcomes)
Changes in renal function between Alcovit® administration groups before and after alcohol ingestion (distilled and fermented beverages) compared to control for urea, creatinine, electrolytes, and urinalysis.
Time frame: Day 1 to Day 44 (6 weeks)
Ease of Handling and Administration (Clinician-Reported Outcomes/Patient-Reported Outcomes)
Ease of handling and administration of Alcovit® assessed by questionnaire administered to nursing staff.
Time frame: Day 1.
Baseline Population Characteristics (Clinician-Reported Outcomes)
Characterization of the study population and identification of potential confounding factors.
Time frame: Day 1 (baseline)
Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality in accordance with Brazilian data protection laws (LGPD - Lei Geral de Proteção de Dados) and ethical requirements. Study results will be published in aggregated form only.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2027, 0 months later.
Of 328 non-industry interventional studies with no phase under Alcohol Drinking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 0 months is below that.
Counting every sponsor, half of 336 studies reached it within 24 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start May 2026 → Jan 2027, primary completion May 2026 → Jan 2027 and completion May 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Galzu Institute of Research, Teaching, Science and Applied Technology